Table 3.
Comparisons of stage III NSCLC patients with adenocarcinoma subtype who received surveillance brain MRI and those who did not.
| No Surveillance brain MRI (n = 79) |
Surveillance brain MRI (n = 17) |
|
|---|---|---|
| Developed BrMs: number (%) | ||
| Yes | 25 (31.6%) | 4 (23.5%) |
| No | 54 (68.4%) | 13 (76.5%) |
| BrMs: number (%) | ||
| Symptomatic | 12 (48.0%) | 3 (75.0%) |
| Asymptomatic | 13 (52.0%) | 1 (25.0%) |
BrMs, brain metastases.